Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.

Item
http://www.wikidata.org/entity/Q31098999
Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Need for Prophylactic Treatment in Adult Haemophilia A PatientsPatient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variantNon-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.Blood Clotting Factor VIII: From Evolution to Therapy.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.A critical appraisal of one-stage and chromogenic assays of factor VIII activity.Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
P2860

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.

Item
http://www.wikidata.org/entity/Q31098999
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@ast
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@en
type
label
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@ast
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@en
prefLabel
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@ast
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Efficacy, safety and tolerabil ...... study in Germany and Austria.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2516.2006.01416.X
P433
P478
P577
P698
P921